Skip to main content

Table 2 Phase III trials of bevacizumab in combination with chemotherapy in metastatic breast cancer

From: Antiangiogenic therapy for breast cancer

Reference Number of patients Therapy ORR (%) PFS (months)
Miller et al. [19] 232 B (15 mg/kg q3w) + capecitabine 20 (previous anthracycline and taxane) 5 (TTP)
  230 Capecitabine 9 (P = 0.001) 4
Miller et al. [20] (E2100) 368 (347 intent-to-treat) B (10 mg/kg q2w) + paclitaxel 37 (1st line) 12 (TTP)
  354 (326 intent-to-treat) Paclitaxel 21 6 (P < 0.001)
Miles et al. [21] (AVADO) 248 B (7.5 mg/kg q3w) + docetaxel 55 (1st line) 9 (P = 0.045)
  247 B (15 mg/kg q3w) + docetaxel 64 10 (P < 0.001)
  241 Placebo + docetaxel 46 8
Robert et al. [22] (RIBBON-1) 409 B (15mg/kg q3w) + capecitabine 35 (1st line) 10 (P = 0.0011)
  206 Capecitabine 24 6
  415 B (15 mg/kg q3w) + taxane or anthracycline-based therapy 51 11 (P = 0.040)
  207 Taxane or anthracycline-based therapy 38 8
Brufsky et al. [24, 25] (RIBBON-2) 684 B + chemotherapy (capecitabine, gemcitabine, vinorelbine) 40 (2nd line) 7 (P = 0.0072)
   Chemotherapy 30 5
  1. B, bevacizumab; ORR, overall response rate; PFS, progression free survival; q2w, every second week; q3w, every third week; TTP, time to progression.